Follow
Sara García-Alonso PhD
Sara García-Alonso PhD
CNIO (Spanish National Cancer Research Centre)
Verified email at cnio.es
Title
Cited by
Cited by
Year
Resistance to antibody–drug conjugates
S Garcia-Alonso, A Ocana, A Pandiella
Cancer research 78 (9), 2159-2165, 2018
1562018
Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity
C Ríos-Luci, S García-Alonso, E Díaz-Rodríguez, M Nadal-Serrano, ...
Cancer research 77 (17), 4639-4651, 2017
1202017
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
MA Sabbaghi, G Gil-Gómez, C Guardia, S Servitja, O Arpí, ...
Clinical Cancer Research 23 (22), 7006-7019, 2017
792017
Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond
S García-Alonso, A Ocaña, A Pandiella
Trends in cancer 6 (2), 130-146, 2020
782020
p73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFβ signaling
R Fernandez-Alonso, M Martin-Lopez, L Gonzalez-Cano, S Garcia, ...
Cell Death & Differentiation 22 (8), 1287-1299, 2015
632015
RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression
M Sanclemente, P Nieto, S Garcia-Alonso, F Fernández-García, ...
Cancer cell 39 (3), 294-296, 2021
212021
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
JC Montero, S García-Alonso, A Ocaña, A Pandiella
Oncotarget 6 (30), 30057, 2015
192015
Refining early antitumoral drug development
A Ocaña, S García-Alonso, E Amir, A Pandiella
Trends in Pharmacological Sciences 39 (11), 922-925, 2018
182018
Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation
S García-Alonso, P Mesa, L de la Puente Ovejero, G Aizpurua, ...
Molecular cell 82 (18), 3438-3452. e8, 2022
172022
KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors
G Paniagua, HKC Jacob, O Brehey, S García‐Alonso, CG Lechuga, ...
Molecular oncology 16 (17), 3066-3081, 2022
122022
Multisite phosphorylation of P-Rex1 by protein kinase C
JC Montero, S Seoane, S García-Alonso, A Pandiella
Oncotarget 7 (47), 77937, 2016
82016
mTOR inhibition and T-DM1 in HER2-positive breast cancer
D Casadevall, A Hernández-Prat, S García-Alonso, O Arpí-Llucià, ...
Molecular Cancer Research 20 (7), 1108-1121, 2022
72022
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma
S García-Alonso, I Romero-Pérez, L Gandullo-Sánchez, L Chinchilla, ...
Journal of Experimental & Clinical Cancer Research 40, 1-13, 2021
32021
The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib
A Sánchez‐Fdez, S Matilla‐Almazán, JC Montero, S Del Carmen, M Abad, ...
Clinical and Translational Medicine 13 (4), e1217, 2023
2023
Supplementary files of the article KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors [Dataset]
G Paniagua, HKC Jacob, O Brehey, S García-Alonso, CG Lechuga, ...
John Wiley & Sons, 2022
2022
mTOR inhibition and T-DM1 in HER2-positive breast cancer
D Casadevall Aguilar, A Hernández Prat, S García-Alonso, O Arpí Llucià, ...
Mol Cancer Res. 2022 Jul 6; 20 (7): 1108-21, 2022
2022
Identificación de genes responsables de la respuesta a trastuzumab en cáncer de mama HER2 positivo
L Díaz-Gil, C Locatelli, A Orive-Ramos, P Tomás-Martín, S García Alonso, ...
2018
Anticuerpos conjugados a fármacos frente a receptores ERBB: nuevas indicaciones y mecanismos de resistencia
S García Alonso
2018
The system can't perform the operation now. Try again later.
Articles 1–18